ACROBiosystems – Targets for Antibody-Drug Conjugates|Tokyo Future Style is a bio-tech trading company

BACKGROUNDHOT TARGETSPRODUCT LISTPRODUCT FEATURES

Background

ADCs (Antibody-drug conjugates) are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens with highly potent anti-cancer agents linked via a chemical linker, while sparing normal cells from damage, potentially minimizing the side effects associated with cancer therapy. Currently, there are nine approved drugs on the market.

Related Page: Introduction of ACROBiosystems

Hot targets

ACROBiosystems has developed a series of products with different species and tags for a variety of hot targets, which are suitable for immune, antibody screening, SPR, cell activity detection and other experiments. ACROBiosystems is committed to assisting you in drug development, and all SPR&BLI protocols are available for free. In addition, over expressed cell lines and kit products will be coming soon.

Product list

ACROBiosystems is continuously developing more high-quality targeting proteins of ADCs. If you have any suggestions or customized requirements, please contact Tokyo Future Style.

Back to Top

Product Features

High purity verified by MALS

Fig1.The purity of Human Her2, His Tag (Cat. No. HE2-H5225) was more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.

Fig 2.The purity of Human EGF R, His Tag(Cat. No. EGR-H5222) was more than 90% and the molecular weight of this protein is around 90-115 kDa verified by SEC-MALS.

High affinity validated by SPR&BLI

Fig 3.Herceptin (Trastuzumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay.	Fig 4.Loaded Herceptin (Trastuzumab) on AHC Biosensor, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 0.825 nM as determined in BLI assay.
Fig 5.Erbitux (Cetuximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.3 nM as determined in a SPR assay.	Fig 6.Loaded Erbitux (Cetuximab) on AHC Biosensor, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.23 nM as determined in BLI assay.

Back to Top